| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.90(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,779 |
31,779 |
108,516 |
523,205 |
| Total Sell Value |
$459,589 |
$703,188 |
$3,015,597 |
$13,848,977 |
| Total People Sold |
2 |
3 |
4 |
6 |
| Total Sell Transactions |
5 |
6 |
14 |
32 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anderson Bonnie H |
Director |
– • – |
2023-03-15 |
4 |
AS |
$22.76 |
$773,888 |
D/D |
(34,000) |
53,967 |
|
25% |
|
| Anderson Bonnie H |
Director |
– • – |
2023-03-15 |
4 |
OE |
$5.61 |
$190,740 |
D/D |
34,000 |
87,967 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
78,044 |
230,899 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
8,868 |
28,614 |
|
- |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
23,413 |
54,818 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
26,014 |
96,937 |
|
- |
|
| Anderson Bonnie H |
Director |
– • – |
2023-03-02 |
4 |
D |
$24.10 |
$216,755 |
D/D |
(8,994) |
53,967 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2023-03-02 |
4 |
D |
$24.10 |
$145,299 |
D/D |
(6,029) |
152,855 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
D |
$24.10 |
$65,697 |
D/D |
(2,726) |
70,923 |
|
- |
|
| Mcguire Annie |
SVP, General Counsel |
• – – |
2023-03-02 |
4 |
D |
$24.10 |
$51,863 |
D/D |
(2,152) |
31,405 |
|
- |
|
| Wygant Jonathan |
VP, Chief Accounting Officer |
• – – |
2023-03-02 |
4 |
D |
$24.10 |
$29,498 |
D/D |
(1,224) |
19,746 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2023-02-28 |
4 |
AS |
$25.00 |
$250,001 |
D/D |
(10,000) |
23,451 |
|
2% |
|
| Eastham Karin |
Director |
– • – |
2023-02-28 |
4 |
OE |
$12.12 |
$121,200 |
D/D |
10,000 |
33,451 |
|
- |
|
| Anderson Bonnie H |
Director |
– • – |
2023-01-17 |
4 |
AS |
$26.30 |
$895,838 |
D/D |
(34,000) |
62,961 |
|
-5% |
|
| Anderson Bonnie H |
Director |
– • – |
2023-01-17 |
4 |
OE |
$5.61 |
$190,740 |
D/D |
34,000 |
96,961 |
|
- |
|
| Anderson Bonnie H |
Director |
– • – |
2023-01-11 |
4 |
AS |
$25.13 |
$1,589,195 |
D/D |
(63,247) |
62,961 |
|
4% |
|
| Anderson Bonnie H |
Director |
– • – |
2023-01-11 |
4 |
OE |
$14.34 |
$906,962 |
D/D |
63,247 |
126,208 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2022-12-14 |
4 |
AS |
$30.13 |
$18,080 |
D/D |
(600) |
50,184 |
|
-25% |
|
| Jones Evan/ Fa |
Director |
– • – |
2022-12-13 |
4 |
AS |
$30.51 |
$51,197 |
D/D |
(1,667) |
50,784 |
|
-26% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-12-06 |
4 |
AS |
$27.03 |
$27,652 |
D/D |
(1,023) |
65,970 |
|
-16% |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2022-12-02 |
4 |
D |
$29.14 |
$29,490 |
D/D |
(1,012) |
158,299 |
|
- |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2022-12-02 |
4 |
D |
$29.14 |
$59,504 |
D/D |
(2,042) |
62,961 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2022-12-02 |
4 |
D |
$29.14 |
$21,418 |
D/D |
(735) |
72,998 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-12-02 |
4 |
D |
$29.14 |
$29,373 |
D/D |
(1,008) |
66,993 |
|
- |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2022-12-01 |
4 |
AS |
$27.81 |
$2,260,748 |
D/D |
(80,000) |
65,003 |
|
-21% |
|
557 Records found
|
|
Page 4 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.40 (1.77%) 
